Capivasertib plus fulvestrant for high-risk lobular breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a postmenopausal woman aged 18 or older.
- You have been diagnosed with invasive lobular breast cancer (confirmed by a central lab) that has not been treated yet.
- Your cancer is hormone-receptor positive (at least 10% cells positive) and HER2-negative.
- Your cancer is high-risk, meaning it is either at least 2 cm in size or has spread to lymph nodes (confirmed by imaging or biopsy).
- You have not had any prior treatment for this breast cancer (including hormone therapy, chemotherapy, or targeted therapy).
- Your overall health is good (ECOG score 0 or 1) and your heart, blood, and organ function are within study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug capivasertib to standard hormone therapy works better for metastatic breast cancer that is HR positive and HER2 negative. It uses a blood test (ctDNA) to monitor response.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
Hear when a new CCCA Assessed by Ki67 Drop Below <2.7% From Baseline trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.